The Impact of Sarcopenia in Patients with Peritoneal Surface Disease
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is increasingly performed in patients with advanced cancer in the abdomen. This treatment prolongs survival for some patients but is known to have a substantial rate of complications. Choosing patients for this procedure can be diff...
Gespeichert in:
| Veröffentlicht in: | Pathology oncology research 2021-08, Vol.27, p.638857-638857 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 638857 |
|---|---|
| container_issue | |
| container_start_page | 638857 |
| container_title | Pathology oncology research |
| container_volume | 27 |
| creator | Juris, Aubrey Taylor-Gehman, Amanda Spencer, Brianna Schaefer, Eric Pameijer, Colette |
| description | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is increasingly performed in patients with advanced cancer in the abdomen. This treatment prolongs survival for some patients but is known to have a substantial rate of complications. Choosing patients for this procedure can be difficult, and no clear guidelines exist. Muscle mass is a general measure of a patient's wellness, meaning that patients with low muscle mass for their body weight tend to have more complications from treatment and overall do worse. We evaluated muscle mass prior to surgery in our Cytoreductive surgery/hyperthermic intraperitoneal chemotherapy population to assess how many patients have low muscle mass and the impact on outcomes, such as length of hospital stay, complications and survival. We find that about 25% of our patient population has low muscle mass, and low muscle mass is associated with a higher burden of cancer and shorter survival. We were able to evaluate muscle mass in a small number of patients after surgery, expecting to find decreased muscle mass in all the patients after a complex operation and long recovery. In fact, none of the patients had low muscle mass, including those who were low prior to surgery. |
| doi_str_mv | 10.3389/pore.2021.638857 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8435582</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2574787301</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-e5ee01588a1d09513c6e37c684ed8198cc7e9fad3a23c08334c25723d780f86a3</originalsourceid><addsrcrecordid>eNpdkU1LxDAQhoMoun7cPUnAi5ddk0zTpBdB_IYFBddziOnUjXSbmrSK_94uq7J6ykCeeWeGh5BDziYAujhtQ8SJYIJPctBaqg0y4hLEWGimNtfqHbKb0itjTOVFvk12IJMiH_gRuZzNkd4tWus6Gir6aKMLLTbeUt_QB9t5bLpEP3w3pw8YfRcatDV97GNlHdJLn9Am3Cdbla0THny_e-Tp-mp2cTue3t_cXZxPxy4TWTdGici41NrykhWSg8sRlMt1hqXmhXZOYVHZEqwAxzRA5oRUAkqlWaVzC3vkbJXb9s8LLN2wW7S1aaNf2PhpgvXm70_j5-YlvBudgZRaDAEn3wExvPWYOrPwyWFd2wZDn8wwDjJQLIcBPf6HvoY-NsN5SypTWgHjA8VWlIshpYjV7zKcmaUis1RklorMStHQcrR-xG_DjxP4AnlDjM4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2574787301</pqid></control><display><type>article</type><title>The Impact of Sarcopenia in Patients with Peritoneal Surface Disease</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Juris, Aubrey ; Taylor-Gehman, Amanda ; Spencer, Brianna ; Schaefer, Eric ; Pameijer, Colette</creator><creatorcontrib>Juris, Aubrey ; Taylor-Gehman, Amanda ; Spencer, Brianna ; Schaefer, Eric ; Pameijer, Colette</creatorcontrib><description>Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is increasingly performed in patients with advanced cancer in the abdomen. This treatment prolongs survival for some patients but is known to have a substantial rate of complications. Choosing patients for this procedure can be difficult, and no clear guidelines exist. Muscle mass is a general measure of a patient's wellness, meaning that patients with low muscle mass for their body weight tend to have more complications from treatment and overall do worse. We evaluated muscle mass prior to surgery in our Cytoreductive surgery/hyperthermic intraperitoneal chemotherapy population to assess how many patients have low muscle mass and the impact on outcomes, such as length of hospital stay, complications and survival. We find that about 25% of our patient population has low muscle mass, and low muscle mass is associated with a higher burden of cancer and shorter survival. We were able to evaluate muscle mass in a small number of patients after surgery, expecting to find decreased muscle mass in all the patients after a complex operation and long recovery. In fact, none of the patients had low muscle mass, including those who were low prior to surgery.</description><identifier>ISSN: 1532-2807</identifier><identifier>ISSN: 1219-4956</identifier><identifier>EISSN: 1532-2807</identifier><identifier>DOI: 10.3389/pore.2021.638857</identifier><identifier>PMID: 34526857</identifier><language>eng</language><publisher>Switzerland: Frontiers Media SA</publisher><subject>Abdomen ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Cancer therapies ; Chemotherapy ; Clinical outcomes ; Colorectal cancer ; Combined Modality Therapy - methods ; Cytoreduction Surgical Procedures - methods ; Female ; Histology ; Humans ; Hyperthermia, Induced - methods ; Length of stay ; Male ; Medical imaging ; Metastasis ; Middle Aged ; Muscles - pathology ; Musculoskeletal system ; Overweight ; Patients ; Peritoneal Neoplasms - pathology ; Retrospective Studies ; Sarcopenia ; Sarcopenia - pathology ; Sarcopenia - therapy ; Society Journal Archive ; Surgery ; Womens health ; Young Adult</subject><ispartof>Pathology oncology research, 2021-08, Vol.27, p.638857-638857</ispartof><rights>Copyright © 2021 Juris, Taylor-Gehman, Spencer, Schaefer and Pameijer.</rights><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2021 Juris, Taylor-Gehman, Spencer, Schaefer and Pameijer. 2021 Juris, Taylor-Gehman, Spencer, Schaefer and Pameijer</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-e5ee01588a1d09513c6e37c684ed8198cc7e9fad3a23c08334c25723d780f86a3</citedby><cites>FETCH-LOGICAL-c424t-e5ee01588a1d09513c6e37c684ed8198cc7e9fad3a23c08334c25723d780f86a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435582/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435582/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34526857$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Juris, Aubrey</creatorcontrib><creatorcontrib>Taylor-Gehman, Amanda</creatorcontrib><creatorcontrib>Spencer, Brianna</creatorcontrib><creatorcontrib>Schaefer, Eric</creatorcontrib><creatorcontrib>Pameijer, Colette</creatorcontrib><title>The Impact of Sarcopenia in Patients with Peritoneal Surface Disease</title><title>Pathology oncology research</title><addtitle>Pathol Oncol Res</addtitle><description>Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is increasingly performed in patients with advanced cancer in the abdomen. This treatment prolongs survival for some patients but is known to have a substantial rate of complications. Choosing patients for this procedure can be difficult, and no clear guidelines exist. Muscle mass is a general measure of a patient's wellness, meaning that patients with low muscle mass for their body weight tend to have more complications from treatment and overall do worse. We evaluated muscle mass prior to surgery in our Cytoreductive surgery/hyperthermic intraperitoneal chemotherapy population to assess how many patients have low muscle mass and the impact on outcomes, such as length of hospital stay, complications and survival. We find that about 25% of our patient population has low muscle mass, and low muscle mass is associated with a higher burden of cancer and shorter survival. We were able to evaluate muscle mass in a small number of patients after surgery, expecting to find decreased muscle mass in all the patients after a complex operation and long recovery. In fact, none of the patients had low muscle mass, including those who were low prior to surgery.</description><subject>Abdomen</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Clinical outcomes</subject><subject>Colorectal cancer</subject><subject>Combined Modality Therapy - methods</subject><subject>Cytoreduction Surgical Procedures - methods</subject><subject>Female</subject><subject>Histology</subject><subject>Humans</subject><subject>Hyperthermia, Induced - methods</subject><subject>Length of stay</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Muscles - pathology</subject><subject>Musculoskeletal system</subject><subject>Overweight</subject><subject>Patients</subject><subject>Peritoneal Neoplasms - pathology</subject><subject>Retrospective Studies</subject><subject>Sarcopenia</subject><subject>Sarcopenia - pathology</subject><subject>Sarcopenia - therapy</subject><subject>Society Journal Archive</subject><subject>Surgery</subject><subject>Womens health</subject><subject>Young Adult</subject><issn>1532-2807</issn><issn>1219-4956</issn><issn>1532-2807</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkU1LxDAQhoMoun7cPUnAi5ddk0zTpBdB_IYFBddziOnUjXSbmrSK_94uq7J6ykCeeWeGh5BDziYAujhtQ8SJYIJPctBaqg0y4hLEWGimNtfqHbKb0itjTOVFvk12IJMiH_gRuZzNkd4tWus6Gir6aKMLLTbeUt_QB9t5bLpEP3w3pw8YfRcatDV97GNlHdJLn9Am3Cdbla0THny_e-Tp-mp2cTue3t_cXZxPxy4TWTdGici41NrykhWSg8sRlMt1hqXmhXZOYVHZEqwAxzRA5oRUAkqlWaVzC3vkbJXb9s8LLN2wW7S1aaNf2PhpgvXm70_j5-YlvBudgZRaDAEn3wExvPWYOrPwyWFd2wZDn8wwDjJQLIcBPf6HvoY-NsN5SypTWgHjA8VWlIshpYjV7zKcmaUis1RklorMStHQcrR-xG_DjxP4AnlDjM4</recordid><startdate>20210830</startdate><enddate>20210830</enddate><creator>Juris, Aubrey</creator><creator>Taylor-Gehman, Amanda</creator><creator>Spencer, Brianna</creator><creator>Schaefer, Eric</creator><creator>Pameijer, Colette</creator><general>Frontiers Media SA</general><general>Frontiers Media S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210830</creationdate><title>The Impact of Sarcopenia in Patients with Peritoneal Surface Disease</title><author>Juris, Aubrey ; Taylor-Gehman, Amanda ; Spencer, Brianna ; Schaefer, Eric ; Pameijer, Colette</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-e5ee01588a1d09513c6e37c684ed8198cc7e9fad3a23c08334c25723d780f86a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Abdomen</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Clinical outcomes</topic><topic>Colorectal cancer</topic><topic>Combined Modality Therapy - methods</topic><topic>Cytoreduction Surgical Procedures - methods</topic><topic>Female</topic><topic>Histology</topic><topic>Humans</topic><topic>Hyperthermia, Induced - methods</topic><topic>Length of stay</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Muscles - pathology</topic><topic>Musculoskeletal system</topic><topic>Overweight</topic><topic>Patients</topic><topic>Peritoneal Neoplasms - pathology</topic><topic>Retrospective Studies</topic><topic>Sarcopenia</topic><topic>Sarcopenia - pathology</topic><topic>Sarcopenia - therapy</topic><topic>Society Journal Archive</topic><topic>Surgery</topic><topic>Womens health</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Juris, Aubrey</creatorcontrib><creatorcontrib>Taylor-Gehman, Amanda</creatorcontrib><creatorcontrib>Spencer, Brianna</creatorcontrib><creatorcontrib>Schaefer, Eric</creatorcontrib><creatorcontrib>Pameijer, Colette</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pathology oncology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Juris, Aubrey</au><au>Taylor-Gehman, Amanda</au><au>Spencer, Brianna</au><au>Schaefer, Eric</au><au>Pameijer, Colette</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Impact of Sarcopenia in Patients with Peritoneal Surface Disease</atitle><jtitle>Pathology oncology research</jtitle><addtitle>Pathol Oncol Res</addtitle><date>2021-08-30</date><risdate>2021</risdate><volume>27</volume><spage>638857</spage><epage>638857</epage><pages>638857-638857</pages><issn>1532-2807</issn><issn>1219-4956</issn><eissn>1532-2807</eissn><abstract>Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is increasingly performed in patients with advanced cancer in the abdomen. This treatment prolongs survival for some patients but is known to have a substantial rate of complications. Choosing patients for this procedure can be difficult, and no clear guidelines exist. Muscle mass is a general measure of a patient's wellness, meaning that patients with low muscle mass for their body weight tend to have more complications from treatment and overall do worse. We evaluated muscle mass prior to surgery in our Cytoreductive surgery/hyperthermic intraperitoneal chemotherapy population to assess how many patients have low muscle mass and the impact on outcomes, such as length of hospital stay, complications and survival. We find that about 25% of our patient population has low muscle mass, and low muscle mass is associated with a higher burden of cancer and shorter survival. We were able to evaluate muscle mass in a small number of patients after surgery, expecting to find decreased muscle mass in all the patients after a complex operation and long recovery. In fact, none of the patients had low muscle mass, including those who were low prior to surgery.</abstract><cop>Switzerland</cop><pub>Frontiers Media SA</pub><pmid>34526857</pmid><doi>10.3389/pore.2021.638857</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1532-2807 |
| ispartof | Pathology oncology research, 2021-08, Vol.27, p.638857-638857 |
| issn | 1532-2807 1219-4956 1532-2807 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8435582 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Abdomen Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer therapies Chemotherapy Clinical outcomes Colorectal cancer Combined Modality Therapy - methods Cytoreduction Surgical Procedures - methods Female Histology Humans Hyperthermia, Induced - methods Length of stay Male Medical imaging Metastasis Middle Aged Muscles - pathology Musculoskeletal system Overweight Patients Peritoneal Neoplasms - pathology Retrospective Studies Sarcopenia Sarcopenia - pathology Sarcopenia - therapy Society Journal Archive Surgery Womens health Young Adult |
| title | The Impact of Sarcopenia in Patients with Peritoneal Surface Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A40%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Impact%20of%20Sarcopenia%20in%20Patients%20with%20Peritoneal%20Surface%20Disease&rft.jtitle=Pathology%20oncology%20research&rft.au=Juris,%20Aubrey&rft.date=2021-08-30&rft.volume=27&rft.spage=638857&rft.epage=638857&rft.pages=638857-638857&rft.issn=1532-2807&rft.eissn=1532-2807&rft_id=info:doi/10.3389/pore.2021.638857&rft_dat=%3Cproquest_pubme%3E2574787301%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2574787301&rft_id=info:pmid/34526857&rfr_iscdi=true |